Increased demand for high-quality healthcare, is expected to drive sleep aids market expansion in the near future at a CAGR of 7.20% during the forecast period 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Sleep Aids Market” that contains information from 2023 to 2032.

Sleep Aids Market Highlights

The global sleep aids market is accounted to register a CAGR of 7.20% during the forecast period and is estimated to reach USD 112.6 billion by 2032.

The primary market factors boosting market growth are the rise in the elderly and overweight population, the adjustment of sleep patterns brought on by lifestyle changes, the increase in consumer affluence, and the expansion of medical services due to the increased demand for high-quality healthcare. The use of sleep aids and an increase in non-refundable income are driving the expansion of the market for sleep aids. Additionally, there are more elderly and obese people than ever before, which has raised the incidence of sleep disorders. The number of people with sleep problems is predicted to rise as a result, which will contribute to the market's expansion.  

MRFR recognizes the following companies as the key players in the global Sleep Aids market— Acelity L.P. Inc. (Kinetic Concepts, Inc.), AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Drive DeVilbiss Healthcare Inc., Eisai Co., Ltd., Emergent Biosolutions, F.Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Limited, Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc., Koninklijke Philips N.V., Merck and Co. Inc., Natus Medical Incorporated, Novartis AG, Pfizer Inc., ResMed Inc., Sanofi S.A., Serta Simmons Bedding LLC, Sinovac Biotech Ltd., SleepMed Inc., Takeda Pharmaceutical Company Limited, and Tempur Sealy International Inc.

Segment Analysis

The global Sleep Aids market has been segmented based product and sleep-disorder.

On the basis of product, the market is segmented into mattresses & pillows, medications, sleep apnea devices, and others. The mattresses and pillows segment dominated the market for sleep aids in 2022 and is anticipated to hold this position throughout the projection. The configuration of the beds and pillows is likely to change as industrial technology continues to progress.

Based on sleep-disorder, the global sleep aids market has been segmented into insomnia, sleep apnea, restless legs syndrome, narcolepsy, sleep walking, and other sleep disorders. The insomnia segment accounted for the largest market share in 2022 and is anticipated to dominate the market for sleeping aids and its governance in the industry throughout the forecast period due to the rise in healthcare awareness, the rising prevalence of sleep apnea, the decline in people's physical activity, and the advancement of the geriatric population.

Regional Analysis

The global Sleep Aids market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Sleep Aids market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Sleep Aids market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Sleep Aids market comprises of Middle East, Africa, and Latin America.

The largest market share for Sleep Aids was maintained by the North American regional sector. The market share may be explained by the rising incidence of sleep problems in the country as a result of rising tobacco and alcohol consumption.

Moreover, the Europe market has been persistently growing over the forecast period. The market is expected to grow as a result of the presence of important corporate organizations in Europe and the growing consumer awareness of products that promote sleep excellence and support with sleep.

The Asia Pacific Sleep Aids market is expected to register fastest CAGR from 2023 to 2032. The highest pace of business expansion in the Asia-Pacific area is attributable to both the rising profit per capita and the growing public consciousness of the adverse effects on the people.

Furthermore, the rest of the world's Sleep Aids market is divided into the Middle East, Africa, and Latin America. The market is primarily being pushed by the rising prevalence of sleep disorders such sleep apnea, insomnia, and restless leg syndrome as well as the growing understanding of the value of good sleep hygiene.

Key Findings of the Study

• The global Sleep Aids market is expected to reach USD 112.6 billion by 2032, at a CAGR of 7.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the rising profit per capita and the growing public consciousness of the adverse effects on the people


• Based on sleep-disorder, the insomnia segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Acelity L.P. Inc. (Kinetic Concepts, Inc.), AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Drive DeVilbiss Healthcare Inc., Eisai Co., Ltd., Emergent Biosolutions, F.Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Limited, Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc., Koninklijke Philips N.V., Merck and Co. Inc., Natus Medical Incorporated, Novartis AG, Pfizer Inc., ResMed Inc., Sanofi S.A., Serta Simmons Bedding LLC, Sinovac Biotech Ltd., SleepMed Inc., Takeda Pharmaceutical Company Limited, and Tempur Sealy International Inc.